India Pharma Outlook Team | Monday, 28 April 2025
In India 2026, a Japanese major Takeda, plans to launch a vaccine for dengue, Qdenga, to align with the ‘Make-in-India’, partnering with Hyderabad-based Biological E (Bio E).
Derek Wallace, President, Global vaccine business unit, Takeda, said, “We plan to introduce the vaccine in both the private and public sectors simultaneously. The initial conversation aligns with WHO guidelines for implementing public programs for the pediatric population. However, we are introducing the vaccine in the private sector for both pediatric and adult populations.”
He mentioned in his TOI exclusive interview that dengue is recognized as a “global health challenge.” The company will adopt over $23 billion, and he quoted, “a tiered pricing model for its first global vaccine to maximize access.”
To implement their company strategy in India, on a country basis, negotiable prices from centralized govt procurement. As the company focuses on oncology, rare diseases and gastroenterology, now they’re elaborating on the regulatory process. With clinical trials proceeding to generate local safety data, the process is going on its on track.
They have already submitted an inclusive data package to support registration in 40 countries and the anticipated vaccine will be licensed in India by 2026.
They have also planned to introduce the vaccine in both the private and public sectors at once and for both pediatric and adult populations. The initial conversation aligns with WHO's plans for executing public programs for the pediatric population.